Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis - 09/01/21

Doi : 10.1016/j.jaci.2020.04.055

Benjamin Ungar, MD ^a,^{^{∗
These authors contributed equally to this article.}}, Ana B. Pavel, PhD ^a,^{^{∗
These authors contributed equally to this article.}}, Randall Li, BS ^a,^{^{∗
These authors contributed equally to this article.}}, Grace Kimmel, MD ^a, John Nia, MD ^a, Peter Hashim, MD ^a, Hee Jin Kim, MD ^a, Margot Chima, MD ^a, Anjali S. Vekaria, MD ^a, Yeriel Estrada, BS ^a, Hui Xu, MSc ^a, Xiangyu Peng, MSc ^a, Giselle K. Singer, BS ^a, Danielle Baum, RN ^a, Yasaman Mansouri, MD ^a, Mark Taliercio, BS ^a, Emma Guttman-Yassky, MD, PhD ^a,^b,^c
^a Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
^b Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
^c Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY

This study was funded by Novartis Pharmaceuticals Company.

Disclosure of potential conflict of interest: R. Guttman-Yassky has served as a consultant for AbbVie, Amgen, Allergan, Asana Bioscience, Celgene, Concert, Dermira, DS Biopharma, Escalier, Galderma, Glenmark, Kyowa Kirin, LEO Pharmaceuticals, Lilly, Mitsubishi Tanabe, Novartis, Pfizer, Regeneron, Sanofi, and Union Therapeutics; a member of advisory boards of Allergan, Asana Bioscience, Celgene, DBV, Dermavant, Dermira, Escalier, Galderma, Glenmark, Kyowa Kirin, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, and Sanofi; and a recipient of research grants from AbbVie, AnaptysBio, AntibioTx, Asana Bioscience, Boehringer-Ingelheim, Celgene, DBV, Dermavant, DS Biopharma, Galderma, Glenmark, Innovaderm, Janssen Biotech, Kiniska Pharma, LEO Pharmaceuticals, Lilly, Medimmune, Sienna Biopharmaceuticals, Novan, Novartis, Ralexar, Regeneron, Pfizer, UCB, and Union Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest.

Export

Vol 147 - N° 1

P. 394-397 - janvier 2021 Retour au numéro

Article précédent

Protein functionality as a potential bottleneck for somatic revertant variants
Fabian M.P. Kaiser, Ismail Reisli, Ingrid Pico-Knijnenburg, Anton W. Langerak, François G. Kavelaars, Hasibe Artac, Hanna IJspeert, Mirjam van der Burg

| Article suivant

Low-dose capsaicin (0.01 mM) nasal spray is equally effective as the current standard treatment for idiopathic rhinitis: A randomized, double-blind, placebo-controlled trial
Laura Van Gerven, Brecht Steelant, Leen Cools, Ina Callebaut, Wout Backaert, Jan de Hoon, Els Ampe, Karel Talavera, Peter W. Hellings

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis - 09/01/21

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL